No abstract

No abstract

No abstract

These costs yielded an ICER of -4170 for the SOF+LDV+RBV, -9515 for the SOF+DCV and -2289 for the SOF+RBV. SOF+DCV regimen was the most cost saving option for cirrhotic and non-cirrhotic patients than the other treatment regimens. Deterministic sensitivity analyses remain robust. ConClusions: This study concludes that SOF+DCVregimen is the most cost saving option that yields the most favorable future health economic outcomes compared to the SOF+pegIFN+RBV group across a broad spectrum of patients, including those with cirrhosis.

million by using PCC, which represent 0.0053% of the entire Mexican public health budget. Sensitivity analysis corroborated results of base cases. ConClusions: PCC is a cost-saving alternative when compared to FFP in treatment and prophylaxis of bleeding in patients treated with oral anticoagulants under perspective of Health Public Institutions in Mexico.